Recogen 10000 IU (IV/SC Injection)
10000 IU pre-filled syringe: ৳ 3,900.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Erythropoietin alfa |
| Company | Aci limited |
| Also available as |
Indications
- Treatment of anemia due to Chronic Kidney Disease (CKD)
- Treatment of anemia due to Zidovudine in HIV-infected patients
- Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery
- Prevention of anemia of prematurity in infants with a birth weight of 750 to 1500 gm and gestational age of less than 34 weeks
Description
Recombinant human erythropoietin (EPO) expressed in Chinese hamster ovary cells with a 165 amino acid sequence identical to human urinary EPO
Dosage
- Monitor hemoglobin levels at least weekly until stable
- Evaluate iron status in all patients before and during treatment
- Adjust therapy based on hemoglobin rate of rise, rate of decline, and ESA responsiveness
- Starting dose for adult patients with CKD on dialysis: 50 to 100 units/kg 3 times weekly intravenously or subcutaneously
- Starting dose for Zidovudine-treated HIV-infected Patients: 100 units/kg as an intravenous or subcutaneous injection 3 times per week
Administration
- Do not shake or freeze the Erythropoietin alfa
- Protect syringe from light
- Inspect visually for particulate matter and discoloration prior to administration
- Discard unused portions of Erythropoietin alfa
Interaction
Effect may be potentiated by simultaneous therapeutic administration of a haematinic agent such as ferrous sulphate
Contraindications
- Uncontrolled hypertension
- Serious allergic reactions to Erythropoietin alfa
- Patients who develop Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin
Side Effects
- Hypertension, arthralgia, muscle spasm, pyrexia, dizziness, and upper respiratory tract infection in patients with CKD
- Pyrexia, cough, rash, and injection site irritation in Zidovudine-treated HIV-infected Patients
- Nausea, vomiting, myalgia, arthralgia, stomatitis, cough, weight decrease, leukopenia, bone pain, rash, hyperglycemia, headache, depression, dysphagia, hypokalemia, and thrombosis in cancer patients on chemotherapy
- Nausea, vomiting, pruritus, headache, injection site pain, chills, and deep vein thrombosis in surgery patients
- A fall in serum ferritin values in premature infants
Pregnancy & Lactation
- Erythropoietin alfa should be used in pregnancy only if the potential benefit outweighs the potential risk to the foetus
- Not recommended for pregnant or lactating surgical patients participating in an autologous blood predonation programme
- Use with caution in nursing women, decision on whether to continue/discontinue therapy should consider the benefit of breast feeding to the child and the benefit of Erythropoietin alfa therapy to the woman
Overdose Effects
Recogen overdosage can cause hemoglobin levels above the desired level, managed with discontinuation or reduction of Recogen dosage and/or with phlebotomy, as clinically indicated. Severe hypertension has been observed following overdose with ESAs
Therapeutic Class
Drugs for Haemolytic Hypoplastic & Renal Anemia
Storage Conditions
Store at 2°C to 8°C, do not freeze or shake, store in original package to protect from light